Two-Pronged Gene Therapy for Glioblastoma Proves Safe in Phase 1 Trial (2 of 3) (IMAGE)

American Association for the Advancement of Science (AAAS)

Two-Pronged Gene Therapy for Glioblastoma Proves Safe in Phase 1 Trial (2 of 3)

Caption

Glioblastoma from one treated patient at the time of surgical resection (left panels) and 175 days after treatment (right panels). There was a 17-fold increase in the number of tumor-infiltrating immune cells (yellow, green, cyan) after treatment. This material relates to a paper that appeared in the August 14, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by E.A. Chiocca at Brigham and Women's Hospital in Boston, MA; and colleagues was titled, "Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial."

Credit

E.A. Chiocca <i>et al., Science Translational Medicine</i> (2019)

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.